 <h1>Invirase Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>saquinavir</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about saquinavir. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Invirase.</p><h2>In Summary</h2><p><b>Common side effects of Invirase include:</b> abdominal distress, diarrhea, and nausea. <b>Other side effects include:</b> vomiting.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to saquinavir: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, saquinavir (the active ingredient contained in Invirase) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking saquinavir:</p><p>
<i>More common</i>
</p><ul>
<li>Chest pain</li>
<li>chills</li>
<li>cough</li>
<li>fever</li>
<li>increased amount of fat in the upper back and neck, or around the chest and stomach area</li>
<li>loss of fat from the legs, arms, and face</li>
<li>sneezing</li>
<li>sore throat</li>
<li>tightness in the chest</li>
<li>trouble breathing</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>cough-producing mucus</li>
<li>diarrhea</li>
<li>dry mouth</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>general feeling of discomfort or illness</li>
<li>headache</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>joint pain</li>
<li>loss of appetite</li>
<li>loss of consciousness</li>
<li>muscle aches and pains</li>
<li>nausea</li>
<li>runny nose</li>
<li>shivering</li>
<li>skin rash</li>
<li>sore throat</li>
<li>stomachache</li>
<li>sweating</li>
<li>trouble sleeping</li>
<li>unexplained weight loss</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Burning or prickling sensation</li>
<li>confusion</li>
<li>dehydration</li>
<li>dry or itchy skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of saquinavir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Back pain</li>
<li>belching</li>
<li>bloated or full feeling</li>
<li>change in taste</li>
<li>decreased interest in sexual intercourse</li>
<li>difficulty having a bowel movement</li>
<li>discouragement</li>
<li>excess air or gas in the stomach or bowels</li>
<li>fear</li>
<li>feeling sad or empty</li>
<li>headache</li>
<li>heartburn</li>
<li>inability to have or keep an erection</li>
<li>indigestion</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>loss of interest or pleasure</li>
<li>mouth ulcers</li>
<li>nervousness</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>passing gas</li>
<li>skin rash, encrusted, scaly, and oozing</li>
<li>skin warts</li>
<li>stomach upset, discomfort, or pain</li>
<li>stuffy nose</li>
<li>tiredness</li>
<li>trouble concentrating</li>
<li>weakness</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to saquinavir: oral capsule, oral tablet</i></p><h3>General</h3><p>Nausea, vomiting, diarrhea, fatigue, flatulence, and abdominal pain have been reported the most frequently with this drug (plus ritonavir).  Additional side effects have been reported during postmarketing experience that were similar to those observed in clinical trials with saquinavir (the active ingredient contained in Invirase) mesylate and saquinavir soft gel capsules alone or in combination with ritonavir.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea, diarrhea</p>
<p><b>Common</b> (1% to 10%): Vomiting, abdominal distension, abdominal pain, upper abdominal pain, constipation, dry mouth, dyspepsia, eructation, flatulence, lip dry, loose stools, increased blood amylase</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis</p>
<p><b>Frequency not reported</b>: Abdominal discomfort, ascites, bucca mucosa ulceration, dysphagia, gastritis, gastrointestinal (GI) hemorrhage, intestinal obstruction, cheilitis, frequent bowel movements, discolored feces, bloodstained feces, gastralgia, GI inflammation, gingivitis, GI ulcer, glossitis, hemorrhoids, melena, painful defecation, parotid disorder, rectal hemorrhage, salivary gland disorder, stomatitis, tooth disorder, abdominal colic, esophageal ulceration, esophagitis, gastroesophageal reflux, infectious diarrhea, pruritus ani, pyrosis, stomach upset, toothache<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Diabetes mellitus/hyperglycemia was sometimes associated with ketoacidosis during postmarketing experience.</p>
<p></p>
<p>Redistribution/accumulation of body fat has been reported with antiretroviral therapy; causality has not been established.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased blood cholesterol, increased blood triglycerides, increased low-density lipoprotein</p>
<p><b>Common</b> (1% to 10%): Diabetes mellitus/hyperglycemia, anorexia, increased appetite</p>
<p><b>Uncommon</b> (0.1% to 1%): Decreased appetite</p>
<p><b>Frequency not reported</b>: Dehydration, hypertriglyceridemia, increased alkaline phosphatase, increased LDH, hypoglycemia, hyperlipidemia, appetite disturbance, increased blood glucose, decreased blood glucose, hypercalcemia, hypocalcemia, hyperphosphatemia, hypophosphatemia, hyperkalemia, hypokalemia, hypernatremia, hyponatremia</p>
<p><b>Postmarketing reports</b>: Ketoacidosis, metabolic abnormalities (e.g., hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperlactatemia)</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), increased blood lipid levels, increased glucose levels</p>
<p></p>
<p>Protease inhibitor therapy:</p>
<p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, diabetic ketoacidosis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Increased bleeding (including spontaneous skin hematomas and hemarthrosis) in patients with hemophilia type A and B has been associated with protease inhibitors.  In many of the reported cases, treatment with protease inhibitors was continued or restarted and some patients required additional factor VIII.  A causal relationship between protease inhibitor therapy and these episodes has not been established.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Decreased platelet count</p>
<p><b>Common</b> (1% to 10%): Anemia, decreased hemoglobin, decreased lymphocyte count, decreased WBC count</p>
<p><b>Uncommon</b> (0.1% to 1%): Neutropenia</p>
<p><b>Frequency not reported</b>: Hemolytic anemia, leukopenia, lymphadenopathy, pancytopenia, thrombocytopenia, splenomegaly, dermal bleeding, microhemorrhages</p>
<p></p>
<p>Protease inhibitor therapy:</p>
<p>-Frequency not reported: Increased bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs<sup>[Ref]</sup></p><h3>Hepatic</h3><p>There have been reports of worsening liver disease in patients with underlying hepatitis B or C, cirrhosis, chronic alcoholism, and/or other underlying liver abnormalities.</p>
<p></p>
<p>Severe hepatocellular toxicity (which presented as increased hepatic transaminases) occurred in healthy subjects exposed to this drug (plus ritonavir) and rifampin.  Transaminases increased up to more than 20-fold the upper limit of normal in some patients and were associated with GI symptoms (including abdominal pain, gastritis, nausea, vomiting).  Clinical symptoms resolved and hepatic transaminases returned to normal after all 3 drugs were stopped.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Elevated ALT, elevated AST</p>
<p><b>Common</b> (1% to 10%): Increased blood bilirubin</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatitis, jaundice</p>
<p><b>Frequency not reported</b>: Chronic active hepatitis, hepatomegaly, hyperbilirubinemia, portal hypertension, elevated GGT, hepatosplenomegaly, severe cutaneous reaction associated with increased liver function tests, increased transaminase levels, exacerbation of chronic liver disease with grade 4 elevated liver function tests, worsening liver disease, severe hepatocellular toxicity (presenting as increased hepatic transaminases), sclerosing cholangitis, cholelithiasis, liver enzyme disorder<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Second or third degree atrioventricular block</p>
<p><b>Frequency not reported</b>: QT interval prolongation, PR interval prolongation, heart murmur, hypertension, hypotension, thrombophlebitis, vasoconstriction/peripheral vasoconstriction, cyanosis, heart rate disorder, heart valve disorder, vein distension</p>
<p><b>Postmarketing reports</b>: Torsades de pointes (rarely)<sup>[Ref]</sup></p><p>This drug (plus ritonavir) showed a dose-dependent prolongation of the QT and PR intervals.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, fever/pyrexia, asthenia/weakness, increased fat tissue, malaise</p>
<p><b>Uncommon</b> (0.1% to 1%): Mucosal ulceration</p>
<p><b>Frequency not reported</b>: Chest pain, edema, wasting syndrome, intoxication, increased weight, mucosal damage, retrosternal pain, shivering, generalized weakness, earache, ear pressure, otitis, abscess, bacterial infection, candidiasis, herpes simplex, herpes zoster, mycotic infection, staphylococcal infections, decreased weight, external parasites, cellulitis, molluscum contagiosum, moniliasis</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Increased weight<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia, bronchitis, influenza, sinusitis, dyspnea</p>
<p><b>Frequency not reported</b>: Cough, epistaxis, hemoptysis, laryngitis, pharyngitis, respiratory disorder, rhinitis, upper respiratory tract infection, angina tonsillaris, pulmonary disease<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Acquired lipodystrophy, rash, pruritus, dry skin, eczema, alopecia, lipoatrophy</p>
<p><b>Uncommon</b> (0.1% to 1%): Stevens-Johnson syndrome, bullous dermatitis</p>
<p><b>Frequency not reported</b>: Acne, drug eruption, erythema, severe cutaneous reaction associated with increased liver function tests, increased sweating, urticaria, dermatitis, bullous dermatitis skin eruption (including with polyarthritis), folliculitis, furunculosis, hair changes, hot flushes, maculopapular rash, photosensitivity reaction, seborrheic dermatitis, skin disorder, skin nodule, skin pigment changes, skin ulceration, verruca, xeroderma, exanthema, nail disorders, night sweats, psoriasis</p>
<p><b>Postmarketing reports</b>: Lipodystrophy (including loss of peripheral and facial subcutaneous fat, increased intraabdominal and visceral fat, breast hypertrophy, dorsocervical fat accumulation [buffalo hump])<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, paresthesia, peripheral neuropathy, dizziness, dysgeusia/taste alteration</p>
<p><b>Uncommon</b> (0.1% to 1%): Somnolence, convulsions</p>
<p><b>Frequency not reported</b>: Abnormal coordination, hypoesthesia, intracranial hemorrhage (sometimes leading to death), tremor, loss of consciousness, syncope, tinnitus, dysarthria, dysesthesia, ataxia, extremity numbness, face numbness, facial pain, hyperesthesia, hyperreflexia, hyporeflexia, lethargy, lightheadedness, paresis, poliomyelitis, progressive multifocal leukoencephalopathy, seizures, spasms, decreased hearing, stroke, myelopolyradiculoneuritis, prickly sensation<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Decreased libido, sleep disorder</p>
<p><b>Frequency not reported</b>: Anxiety/anxiety attack, confusion/confusional state, depression, insomnia, libido disorder, psychotic disorder/psychosis, suicide attempt, agitation, amnesia, euphoria, excessive dreaming, hallucination, irritability, overdose effect, psychic disorders, reduced intellectual ability, speech disorder<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, muscle spasms</p>
<p><b>Frequency not reported</b>: Arthralgia, myalgia, polyarthritis, elevated blood creatine phosphokinase, arthritis, muscle cramps, musculoskeletal pain, musculoskeletal disorders, stiffness, tissue changes, trauma, leg cramps</p>
<p></p>
<p>Combination antiretroviral therapy:</p>
<p>-Frequency not reported: Osteonecrosis</p>
<p></p>
<p>Protease inhibitor therapy:</p>
<p>-Rare (less than 0.1%): Rhabdomyolysis</p>
<p>-Frequency not reported: Increased creatine phosphokinase, myalgia, myositis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity</p>
<p><b>Frequency not reported</b>: Allergic reaction, drug fever<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increased blood creatinine</p>
<p><b>Uncommon</b> (0.1% to 1%): Renal impairment</p>
<p><b>Frequency not reported</b>: Nephrolithiasis, acute renal insufficiency<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Visual impairment</p>
<p><b>Frequency not reported</b>: Blepharitis, dry eye syndrome, eye irritation, visual disturbance, xerophthalmia, chalazion, cytomegalovirus retinitis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Enlarged prostate, pelvic pain, vaginal discharge, micturition disorder, urinary tract infection, epididymitis, impotence, menstrual disorder, menstrual irregularity, nocturia, penis disorder, renal calculus, renal colic, urinary tract bleeding<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Acute myeloid leukemia, papillomatosis, skin papilloma, tumor<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Hyperprolactinemia, increased thyroid stimulating hormone<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Ribera E,  Azuaje C,  Lopez RM, et al. "Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis." J Antimicrob Chemother 59 (2007): 690-7</p><p id="ref_2">2. Kakuda TN,  Falcon RW "Effect of Food and Ranitidine on Saquinavir Pharmacokinetics and Gastric pH in Healthy Volunteers." Pharmacotherapy 26 (2006): 1060-8</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&amp;mid."  </p><p id="ref_5">5. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_6">6. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_7">7. Modjtahedi BS,  Modjtahedi SP,  Maibach HI "Gender: a possible determinant in dosing of dermatologic drugs--an overview." Cutan Ocul Toxicol 25 (2006): 195-210</p><p id="ref_8">8. "Product Information. Invirase (saquinavir)." Roche Laboratories, Nutley, NJ. </p><p id="ref_9">9. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_10">10. Anderson PL "Pharmacologic perspectives for once-daily antiretroviral therapy." Ann Pharmacother 38 (2004): 1969-70</p><p id="ref_11">11. AIDSinfo. NIH. National Institutes of Health "Guidelines for the Use of Antiretroviral Agents in
Pediatric HIV Infection. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2016 Mar 1]):</p><p id="ref_12">12. "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ. </p><p id="ref_13">13. Figgitt DP, Plosker GL "Saquinavir soft-gel capsule - An updated review of its use in the management of HIV infection." Drugs 60 (2000): 481-516</p><p id="ref_14">14. von Hentig N,  Muller A,  Rottmann C, et al. "Pharmacokinetics of saquinavir, atazanavir and ritonavir in a boosted double-protease inhibitor twice-daily regimen." Antimicrob Agents Chemother 51 (2007): 1431-9</p><p id="ref_15">15. Melbourne: Therapeutic Guidelines Limited "eTG complete [Online] Available from: URL: http://online.tg.org.au/complete/desktop/tgc.htm."   ([2014, Nov -]):</p><p id="ref_16">16. Gill MJ "Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population." AIDS 12 (1998): 1400-2</p><p id="ref_17">17. Panel on Antiretroviral Guidelines for Adults and Adolescents "Guidelines for the use of antiretroviral
agents in HIV-1-infected adults and adolescents. Department of Health and
Human Services. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   (4/8/2015):</p><p id="ref_18">18. Carr A "HIV protease inhibitor-related lipodystrophy syndrome." Clin Infect Dis 30 (2000): s135-42</p><p id="ref_19">19. Lotsch J,  Harder S,  Geisslinger G, et al. "Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor susceptible HIV-1." Antimicrob Agents Chemother 51 (2007): 3264-72</p><p id="ref_20">20. Zorrilla CD,  Van Dyke R,  Bardeguez A, et al. "Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants." Antimicrob Agents Chemother 51 (2007): 2208-10</p><p id="ref_21">21. Cameron DW,  Becker S,  King MS, et al. "Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen." J Antimicrob Chemother 59 (2007): 957-63</p><p id="ref_22">22. FDA. U.S. Food and Drug Administration "FDA drug safety communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm201221.h"   ([2010 Feb 23]):</p><p id="ref_23">23. Biondi L "Health Canada endorsed important safety information on Invirase (saquinavir mesylate). Available from: URL: http://hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/advisories-avis/prof/2010/invirase_hpc-cps-eng.pdf."   ([2010 Apr 14]):</p><p id="ref_24">24. Martinez E, Mocroft A, GarciaViejo MA, PerezCuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell "Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study." Lancet 357 (2001): 592-8</p><p id="ref_25">25. Silva M, Skolnik PR, Gorbach SL, Spiegelman D, Wilson IB, FernandezDiFranco MG, Knox TA "The effect of protease inhibitors on weight and body composition in HIV-infected patients." AIDS 12 (1998): 1645-51</p><p id="ref_26">26. GarciaSilva J, Almagro M, Juega J, Pena C, LopezCalvo S, delPozo J, Fonseca E "Protease inhibitor-related paronychia, ingrown toenails, desquamative cheilitis and cutaneous xerosis." Aids 14 (2000): 1289-91</p><p id="ref_27">27. Roling J,  Schmid H,  Fischereder M,  Draenert R,  Goebel FD "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis 42 (2006): 1488-95</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Invirase (saquinavir)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: protease inhibitors</li>
<li>FDA Alerts (3)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Invirase &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
<li>Occupational Exposure</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to saquinavir: oral capsule, oral tablet</i></p><h3>General</h3><p>Nausea, vomiting, diarrhea, fatigue, flatulence, and abdominal pain have been reported the most frequently with this drug (plus ritonavir).  Additional side effects have been reported during postmarketing experience that were similar to those observed in clinical trials with saquinavir (the active ingredient contained in Invirase) mesylate and saquinavir soft gel capsules alone or in combination with ritonavir.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea, diarrhea</p><p><b>Common</b> (1% to 10%): Vomiting, abdominal distension, abdominal pain, upper abdominal pain, constipation, dry mouth, dyspepsia, eructation, flatulence, lip dry, loose stools, increased blood amylase</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis</p><p><b>Frequency not reported</b>: Abdominal discomfort, ascites, bucca mucosa ulceration, dysphagia, gastritis, gastrointestinal (GI) hemorrhage, intestinal obstruction, cheilitis, frequent bowel movements, discolored feces, bloodstained feces, gastralgia, GI inflammation, gingivitis, GI ulcer, glossitis, hemorrhoids, melena, painful defecation, parotid disorder, rectal hemorrhage, salivary gland disorder, stomatitis, tooth disorder, abdominal colic, esophageal ulceration, esophagitis, gastroesophageal reflux, infectious diarrhea, pruritus ani, pyrosis, stomach upset, toothache<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Diabetes mellitus/hyperglycemia was sometimes associated with ketoacidosis during postmarketing experience.</p><p></p><p>Redistribution/accumulation of body fat has been reported with antiretroviral therapy; causality has not been established.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased blood cholesterol, increased blood triglycerides, increased low-density lipoprotein</p><p><b>Common</b> (1% to 10%): Diabetes mellitus/hyperglycemia, anorexia, increased appetite</p><p><b>Uncommon</b> (0.1% to 1%): Decreased appetite</p><p><b>Frequency not reported</b>: Dehydration, hypertriglyceridemia, increased alkaline phosphatase, increased LDH, hypoglycemia, hyperlipidemia, appetite disturbance, increased blood glucose, decreased blood glucose, hypercalcemia, hypocalcemia, hyperphosphatemia, hypophosphatemia, hyperkalemia, hypokalemia, hypernatremia, hyponatremia</p><p><b>Postmarketing reports</b>: Ketoacidosis, metabolic abnormalities (e.g., hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperlactatemia)</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), increased blood lipid levels, increased glucose levels</p><p></p><p>Protease inhibitor therapy:</p><p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, diabetic ketoacidosis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Increased bleeding (including spontaneous skin hematomas and hemarthrosis) in patients with hemophilia type A and B has been associated with protease inhibitors.  In many of the reported cases, treatment with protease inhibitors was continued or restarted and some patients required additional factor VIII.  A causal relationship between protease inhibitor therapy and these episodes has not been established.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Decreased platelet count</p><p><b>Common</b> (1% to 10%): Anemia, decreased hemoglobin, decreased lymphocyte count, decreased WBC count</p><p><b>Uncommon</b> (0.1% to 1%): Neutropenia</p><p><b>Frequency not reported</b>: Hemolytic anemia, leukopenia, lymphadenopathy, pancytopenia, thrombocytopenia, splenomegaly, dermal bleeding, microhemorrhages</p><p></p><p>Protease inhibitor therapy:</p><p>-Frequency not reported: Increased bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs<sup>[Ref]</sup></p><h3>Hepatic</h3><p>There have been reports of worsening liver disease in patients with underlying hepatitis B or C, cirrhosis, chronic alcoholism, and/or other underlying liver abnormalities.</p><p></p><p>Severe hepatocellular toxicity (which presented as increased hepatic transaminases) occurred in healthy subjects exposed to this drug (plus ritonavir) and rifampin.  Transaminases increased up to more than 20-fold the upper limit of normal in some patients and were associated with GI symptoms (including abdominal pain, gastritis, nausea, vomiting).  Clinical symptoms resolved and hepatic transaminases returned to normal after all 3 drugs were stopped.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Elevated ALT, elevated AST</p><p><b>Common</b> (1% to 10%): Increased blood bilirubin</p><p><b>Uncommon</b> (0.1% to 1%): Hepatitis, jaundice</p><p><b>Frequency not reported</b>: Chronic active hepatitis, hepatomegaly, hyperbilirubinemia, portal hypertension, elevated GGT, hepatosplenomegaly, severe cutaneous reaction associated with increased liver function tests, increased transaminase levels, exacerbation of chronic liver disease with grade 4 elevated liver function tests, worsening liver disease, severe hepatocellular toxicity (presenting as increased hepatic transaminases), sclerosing cholangitis, cholelithiasis, liver enzyme disorder<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Second or third degree atrioventricular block</p><p><b>Frequency not reported</b>: QT interval prolongation, PR interval prolongation, heart murmur, hypertension, hypotension, thrombophlebitis, vasoconstriction/peripheral vasoconstriction, cyanosis, heart rate disorder, heart valve disorder, vein distension</p><p><b>Postmarketing reports</b>: Torsades de pointes (rarely)<sup>[Ref]</sup></p><p>This drug (plus ritonavir) showed a dose-dependent prolongation of the QT and PR intervals.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, fever/pyrexia, asthenia/weakness, increased fat tissue, malaise</p><p><b>Uncommon</b> (0.1% to 1%): Mucosal ulceration</p><p><b>Frequency not reported</b>: Chest pain, edema, wasting syndrome, intoxication, increased weight, mucosal damage, retrosternal pain, shivering, generalized weakness, earache, ear pressure, otitis, abscess, bacterial infection, candidiasis, herpes simplex, herpes zoster, mycotic infection, staphylococcal infections, decreased weight, external parasites, cellulitis, molluscum contagiosum, moniliasis</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Increased weight<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia, bronchitis, influenza, sinusitis, dyspnea</p><p><b>Frequency not reported</b>: Cough, epistaxis, hemoptysis, laryngitis, pharyngitis, respiratory disorder, rhinitis, upper respiratory tract infection, angina tonsillaris, pulmonary disease<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Acquired lipodystrophy, rash, pruritus, dry skin, eczema, alopecia, lipoatrophy</p><p><b>Uncommon</b> (0.1% to 1%): Stevens-Johnson syndrome, bullous dermatitis</p><p><b>Frequency not reported</b>: Acne, drug eruption, erythema, severe cutaneous reaction associated with increased liver function tests, increased sweating, urticaria, dermatitis, bullous dermatitis skin eruption (including with polyarthritis), folliculitis, furunculosis, hair changes, hot flushes, maculopapular rash, photosensitivity reaction, seborrheic dermatitis, skin disorder, skin nodule, skin pigment changes, skin ulceration, verruca, xeroderma, exanthema, nail disorders, night sweats, psoriasis</p><p><b>Postmarketing reports</b>: Lipodystrophy (including loss of peripheral and facial subcutaneous fat, increased intraabdominal and visceral fat, breast hypertrophy, dorsocervical fat accumulation [buffalo hump])<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, paresthesia, peripheral neuropathy, dizziness, dysgeusia/taste alteration</p><p><b>Uncommon</b> (0.1% to 1%): Somnolence, convulsions</p><p><b>Frequency not reported</b>: Abnormal coordination, hypoesthesia, intracranial hemorrhage (sometimes leading to death), tremor, loss of consciousness, syncope, tinnitus, dysarthria, dysesthesia, ataxia, extremity numbness, face numbness, facial pain, hyperesthesia, hyperreflexia, hyporeflexia, lethargy, lightheadedness, paresis, poliomyelitis, progressive multifocal leukoencephalopathy, seizures, spasms, decreased hearing, stroke, myelopolyradiculoneuritis, prickly sensation<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Decreased libido, sleep disorder</p><p><b>Frequency not reported</b>: Anxiety/anxiety attack, confusion/confusional state, depression, insomnia, libido disorder, psychotic disorder/psychosis, suicide attempt, agitation, amnesia, euphoria, excessive dreaming, hallucination, irritability, overdose effect, psychic disorders, reduced intellectual ability, speech disorder<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, muscle spasms</p><p><b>Frequency not reported</b>: Arthralgia, myalgia, polyarthritis, elevated blood creatine phosphokinase, arthritis, muscle cramps, musculoskeletal pain, musculoskeletal disorders, stiffness, tissue changes, trauma, leg cramps</p><p></p><p>Combination antiretroviral therapy:</p><p>-Frequency not reported: Osteonecrosis</p><p></p><p>Protease inhibitor therapy:</p><p>-Rare (less than 0.1%): Rhabdomyolysis</p><p>-Frequency not reported: Increased creatine phosphokinase, myalgia, myositis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity</p><p><b>Frequency not reported</b>: Allergic reaction, drug fever<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increased blood creatinine</p><p><b>Uncommon</b> (0.1% to 1%): Renal impairment</p><p><b>Frequency not reported</b>: Nephrolithiasis, acute renal insufficiency<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Visual impairment</p><p><b>Frequency not reported</b>: Blepharitis, dry eye syndrome, eye irritation, visual disturbance, xerophthalmia, chalazion, cytomegalovirus retinitis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Enlarged prostate, pelvic pain, vaginal discharge, micturition disorder, urinary tract infection, epididymitis, impotence, menstrual disorder, menstrual irregularity, nocturia, penis disorder, renal calculus, renal colic, urinary tract bleeding<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Acute myeloid leukemia, papillomatosis, skin papilloma, tumor<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Hyperprolactinemia, increased thyroid stimulating hormone<sup>[Ref]</sup></p><p id="ref_1">1. Ribera E,  Azuaje C,  Lopez RM, et al. "Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis." J Antimicrob Chemother 59 (2007): 690-7</p><p id="ref_2">2. Kakuda TN,  Falcon RW "Effect of Food and Ranitidine on Saquinavir Pharmacokinetics and Gastric pH in Healthy Volunteers." Pharmacotherapy 26 (2006): 1060-8</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&amp;mid."  </p><p id="ref_5">5. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_6">6. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_7">7. Modjtahedi BS,  Modjtahedi SP,  Maibach HI "Gender: a possible determinant in dosing of dermatologic drugs--an overview." Cutan Ocul Toxicol 25 (2006): 195-210</p><p id="ref_8">8. "Product Information. Invirase (saquinavir)." Roche Laboratories, Nutley, NJ. </p><p id="ref_9">9. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_10">10. Anderson PL "Pharmacologic perspectives for once-daily antiretroviral therapy." Ann Pharmacother 38 (2004): 1969-70</p><p id="ref_11">11. AIDSinfo. NIH. National Institutes of Health "Guidelines for the Use of Antiretroviral Agents in
Pediatric HIV Infection. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2016 Mar 1]):</p><p id="ref_12">12. "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ. </p><p id="ref_13">13. Figgitt DP, Plosker GL "Saquinavir soft-gel capsule - An updated review of its use in the management of HIV infection." Drugs 60 (2000): 481-516</p><p id="ref_14">14. von Hentig N,  Muller A,  Rottmann C, et al. "Pharmacokinetics of saquinavir, atazanavir and ritonavir in a boosted double-protease inhibitor twice-daily regimen." Antimicrob Agents Chemother 51 (2007): 1431-9</p><p id="ref_15">15. Melbourne: Therapeutic Guidelines Limited "eTG complete [Online] Available from: URL: http://online.tg.org.au/complete/desktop/tgc.htm."   ([2014, Nov -]):</p><p id="ref_16">16. Gill MJ "Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population." AIDS 12 (1998): 1400-2</p><p id="ref_17">17. Panel on Antiretroviral Guidelines for Adults and Adolescents "Guidelines for the use of antiretroviral
agents in HIV-1-infected adults and adolescents. Department of Health and
Human Services. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   (4/8/2015):</p><p id="ref_18">18. Carr A "HIV protease inhibitor-related lipodystrophy syndrome." Clin Infect Dis 30 (2000): s135-42</p><p id="ref_19">19. Lotsch J,  Harder S,  Geisslinger G, et al. "Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor susceptible HIV-1." Antimicrob Agents Chemother 51 (2007): 3264-72</p><p id="ref_20">20. Zorrilla CD,  Van Dyke R,  Bardeguez A, et al. "Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants." Antimicrob Agents Chemother 51 (2007): 2208-10</p><p id="ref_21">21. Cameron DW,  Becker S,  King MS, et al. "Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen." J Antimicrob Chemother 59 (2007): 957-63</p><p id="ref_22">22. FDA. U.S. Food and Drug Administration "FDA drug safety communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm201221.h"   ([2010 Feb 23]):</p><p id="ref_23">23. Biondi L "Health Canada endorsed important safety information on Invirase (saquinavir mesylate). Available from: URL: http://hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/advisories-avis/prof/2010/invirase_hpc-cps-eng.pdf."   ([2010 Apr 14]):</p><p id="ref_24">24. Martinez E, Mocroft A, GarciaViejo MA, PerezCuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell "Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study." Lancet 357 (2001): 592-8</p><p id="ref_25">25. Silva M, Skolnik PR, Gorbach SL, Spiegelman D, Wilson IB, FernandezDiFranco MG, Knox TA "The effect of protease inhibitors on weight and body composition in HIV-infected patients." AIDS 12 (1998): 1645-51</p><p id="ref_26">26. GarciaSilva J, Almagro M, Juega J, Pena C, LopezCalvo S, delPozo J, Fonseca E "Protease inhibitor-related paronychia, ingrown toenails, desquamative cheilitis and cutaneous xerosis." Aids 14 (2000): 1289-91</p><p id="ref_27">27. Roling J,  Schmid H,  Fischereder M,  Draenert R,  Goebel FD "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis 42 (2006): 1488-95</p><h2>More about Invirase (saquinavir)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: protease inhibitors</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Invirase &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
<li>Occupational Exposure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>